Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Trillium Therapeutics Inc. (TRIL)

(Delayed Data from NSDQ)

$0.58 USD

+0.01 (1.99%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.58 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[TRIL]

Reports for Purchase

Showing records 1 - 20 ( 54 total )

Industry: Medical - Drugs

Record: 1

10/01/2021

Pages: 3

MOVING TARGET TO ACQUISITION PRICE

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

09/28/2021

Pages: 10

ValuEngine Detailed Valuation Report for TRIL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

08/23/2021

Pages: 6

Pfizer Agrees to Acquire Rest of Trillium; Downgrade to Neutral with $18.50 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

08/16/2021

Pages: 6

Steady Pipeline Progress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

05/10/2021

Pages: 6

Multiple Study Initiations in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

04/29/2021

Pages: 4

More Monotx Responses-Wait Begins for Combo Results

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

04/29/2021

Pages: 4

Multiple Shots on Goal for TTI-622 and TTI-621; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/22/2021

Pages: 6

Expecting Clarity on Clinical Development at R&D Day; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

12/18/2020

Industry Report

Pages: 40

2021 Top Ideas-Healthcare Sector Review/Preview

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

12/16/2020

Industry Report

Pages: 39

2021 Top Ideas

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

12/08/2020

Pages: 5

Skinny ASH.But TRIL Still Well Positioned

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

12/08/2020

Pages: 4

No Surprises at ASH; R&D Day Planned; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

12/06/2020

Pages: 3

Updated results for its TTI-622 monotherapy phase 1 trial

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

11/18/2020

Pages: 6

Clinical Updates Expected at ASH; Higher $22PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

09/10/2020

Pages: 7

Promising Clinical Updates; Pfizer Investment Could Lead to Opportunities; Upgrade to Buy With $16.50 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

09/09/2020

Pages: 3

TTI-622 Continues to Surprise on the Upside; Pfizer Invests

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

08/13/2020

Pages: 7

TTI-622 Update at ASH Could Be an Inflection Point; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

05/29/2020

Pages: 4

Additional TTI-622 Monotherapy Activity

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

05/18/2020

Pages: 6

Eyes on TTI-622 Update at ASCO; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

03/11/2020

Pages: 6

Dose Escalation Studies Progressing; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

previous
1
2
3
next